Xiuning Le1, Robin Cornelissen2, Marina Garassino3, Jeffrey M Clarke4, Nishan Tchekmedyian5, Jonathan W Goldman6, Szu-Yun Leu7, Gajanan Bhat7, Francois Lebel7, John V Heymach1, Mark A Socinski8. 1. Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX. 2. Medical Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands. 3. Medical Thoracic Oncology, Istituto Nazionale dei Tumori di Milano-Fondazione IRCCS, Milan, Italy. 4. Medical Oncology, Duke University Medical Center, Durham, NC. 5. Medical Oncology, Pacific Shores Medical Group, Irvine, CA. 6. David Geffen School of Medicine at UCLA, Los Angeles, CA. 7. Research and Development, Spectrum Pharmaceuticals, Irvine, CA. 8. Thoracic Oncology, AdventHealth Cancer Institute, Orlando, FL.
Abstract
PURPOSE: Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) exon 20 occur in 2%-5% of non-small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib, a tyrosine kinase inhibitor, was evaluated in previously treated patients with NSCLC with HER2 exon 20 insertions. METHODS: ZENITH20, a multicenter, multicohort, open-label phase II study, evaluated poziotinib in patients with advanced or metastatic NSCLC. In cohort 2, patients received poziotinib (16 mg) once daily. The primary end point was objective response rate evaluated by independent review committee (RECIST v1.1); secondary outcome measures were disease control rate, duration of response, progression-free survival, and safety and tolerability. Quality of life was assessed. RESULTS: Between October 2017 and March 2021, 90 patients with a median of two prior lines of therapy (range, 1-6) were treated. With a median follow-up of 9.0 months, objective response rate was 27.8% (95% CI, 18.9 to 38.2); 25 of 90 patients achieved a partial response. Disease control rate was 70.0% (95% CI, 59.4 to 79.2). Most patients (74%) had tumor reduction (median reduction 22%). Median progression-free survival was 5.5 months (95% CI, 3.9 to 5.8); median duration of response was 5.1 months (95% CI, 4.2 to 5.5). Clinical benefit was seen regardless of lines and types of prior therapy, presence of central nervous system metastasis, and types of HER2 mutations. Grade 3 or higher treatment-related adverse events included rash (48.9%), diarrhea (25.6%), and stomatitis (24.4%). Most patients had poziotinib dose reductions (76.7%), with median relative dose intensity of 71.5%. Permanent treatment discontinuation because of treatment-related adverse events occurred in 13.3% of patients. CONCLUSION: Poziotinib demonstrates antitumor activity in previously treated patients with HER2 exon 20 insertion NSCLC.
PURPOSE: Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) exon 20 occur in 2%-5% of non-small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib, a tyrosine kinase inhibitor, was evaluated in previously treated patients with NSCLC with HER2 exon 20 insertions. METHODS: ZENITH20, a multicenter, multicohort, open-label phase II study, evaluated poziotinib in patients with advanced or metastatic NSCLC. In cohort 2, patients received poziotinib (16 mg) once daily. The primary end point was objective response rate evaluated by independent review committee (RECIST v1.1); secondary outcome measures were disease control rate, duration of response, progression-free survival, and safety and tolerability. Quality of life was assessed. RESULTS: Between October 2017 and March 2021, 90 patients with a median of two prior lines of therapy (range, 1-6) were treated. With a median follow-up of 9.0 months, objective response rate was 27.8% (95% CI, 18.9 to 38.2); 25 of 90 patients achieved a partial response. Disease control rate was 70.0% (95% CI, 59.4 to 79.2). Most patients (74%) had tumor reduction (median reduction 22%). Median progression-free survival was 5.5 months (95% CI, 3.9 to 5.8); median duration of response was 5.1 months (95% CI, 4.2 to 5.5). Clinical benefit was seen regardless of lines and types of prior therapy, presence of central nervous system metastasis, and types of HER2 mutations. Grade 3 or higher treatment-related adverse events included rash (48.9%), diarrhea (25.6%), and stomatitis (24.4%). Most patients had poziotinib dose reductions (76.7%), with median relative dose intensity of 71.5%. Permanent treatment discontinuation because of treatment-related adverse events occurred in 13.3% of patients. CONCLUSION: Poziotinib demonstrates antitumor activity in previously treated patients with HER2 exon 20 insertion NSCLC.
Authors: Michael Offin; Daniel Feldman; Ai Ni; Mackenzie L Myers; W Victoria Lai; Elena Pentsova; Adrienne Boire; Mariza Daras; Emmet J Jordan; David B Solit; Maria E Arcila; David R Jones; James M Isbell; Kathryn Beal; Robert J Young; Charles M Rudin; Gregory J Riely; Alexander Drilon; Viviane Tabar; Lisa M DeAngelis; Helena A Yu; Mark G Kris; Bob T Li Journal: Cancer Date: 2019-08-30 Impact factor: 6.860
Authors: Takayuki Kosaka; Junko Tanizaki; Raymond M Paranal; Hideki Endoh; Christine Lydon; Marzia Capelletti; Claire E Repellin; Jihyun Choi; Atsuko Ogino; Antonio Calles; Dalia Ercan; Amanda J Redig; Magda Bahcall; Geoffrey R Oxnard; Michael J Eck; Pasi A Jänne Journal: Cancer Res Date: 2017-03-31 Impact factor: 12.701
Authors: Jacqulyne P Robichaux; Yasir Y Elamin; Zhi Tan; Brett W Carter; Shuxing Zhang; Shengwu Liu; Shuai Li; Ting Chen; Alissa Poteete; Adriana Estrada-Bernal; Anh T Le; Anna Truini; Monique B Nilsson; Huiying Sun; Emily Roarty; Sarah B Goldberg; Julie R Brahmer; Mehmet Altan; Charles Lu; Vassiliki Papadimitrakopoulou; Katerina Politi; Robert C Doebele; Kwok-Kin Wong; John V Heymach Journal: Nat Med Date: 2018-04-23 Impact factor: 53.440
Authors: Hisayuki Shigematsu; Takao Takahashi; Masaharu Nomura; Kuntal Majmudar; Makoto Suzuki; Huei Lee; Ignacio I Wistuba; Kwun M Fong; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; John D Minna; Adi F Gazdar Journal: Cancer Res Date: 2005-03-01 Impact factor: 12.701
Authors: Jacqulyne P Robichaux; Yasir Y Elamin; R S K Vijayan; Monique B Nilsson; Lemei Hu; Junqin He; Fahao Zhang; Marlese Pisegna; Alissa Poteete; Huiying Sun; Shuai Li; Ting Chen; Han Han; Marcelo Vailati Negrao; Jordi Rodon Ahnert; Lixia Diao; Jing Wang; Xiuning Le; Funda Meric-Bernstam; Mark Routbort; Brent Roeck; Zane Yang; Victoria M Raymond; Richard B Lanman; Garrett M Frampton; Vincent A Miller; Alexa B Schrock; Lee A Albacker; Kwok-Kin Wong; Jason B Cross; John V Heymach Journal: Cancer Cell Date: 2019-10-03 Impact factor: 31.743
Authors: Y Wang; T Jiang; Z Qin; J Jiang; Q Wang; S Yang; C Rivard; G Gao; T L Ng; M M Tu; H Yu; H Ji; C Zhou; S Ren; J Zhang; P Bunn; R C Doebele; D R Camidge; F R Hirsch Journal: Ann Oncol Date: 2019-03-01 Impact factor: 32.976
Authors: Anna Michelotti; Marco de Scordilli; Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Alessandra Bearz Journal: Int J Mol Sci Date: 2022-06-17 Impact factor: 6.208
Authors: Arsela Prelaj; Achille Bottiglieri; Gajanan Bhat; Rocky Washington; Giuseppina Calareso; Gabriella Francesca Greco; Roberto Ferrara; Marta Brambilla; Alessandro De Toma; Mario Occhipinti; Sara Manglaviti; Alberto Soro; Monica Ganzinelli; Giuseppe Lo Russo; Claudia Proto Journal: Front Oncol Date: 2022-06-08 Impact factor: 5.738